Nippon India Pharma Fund-Growth
(Scheme Rating)
NAV as of Jun 28, 2024
446.080.77%
- Growth - Regular
(Earn upto 0.90% Extra Returns with Direct Plan)
Fund Category:
Equity: Sectoral-Pharma
Expense Ratio:
1.82%(1.44% Category
average)Fund Size:
Rs. 7,160.93 Cr(30.50% of Investment in Category)
- Invest in NFOADD TO PORTFOLIO
Nippon India Pharma Fund-Growth
(Scheme Rating)
NAV as of Jun 28, 2024
446.080.77%
Expense Ratio:
1.82%
Fund Size:
Rs. 7,160.93 Cr
Fund Category:
Equity: Sectoral-Pharma
1. Current NAV: The Current Net Asset Value of the Nippon India Pharma Fund as of Jun 28, 2024 is Rs 446.08 for Growth option of its Regular plan.
2. Returns: Its trailing returns over different time periods are: 40.79% (1yr), 13.48% (3yr), 25.72% (5yr) and 20.82% (since launch). Whereas, Category returns for the same time duration are: 41.17% (1yr), 13.6% (3yr) and 25.44% (5yr).
3. Fund Size: The Nippon India Pharma Fund currently holds Assets under Management worth of Rs 7160.93 crore as on May 31, 2024.
4. Expense ratio: The expense ratio of the fund is 1.82% for Regular plan as on Jun 21, 2024.
5. Exit Load: Nippon India Pharma Fund shall attract an Exit Load, "Exit load of 1% if redeemed within 1 month."
6. Minimum Investment: Minimum investment required is Rs 5000 and minimum additional investment is Rs 1000. Minimum SIP investment is Rs 100.
Nippon India Pharma Fund-Growth Returns
Trailing Returns
Rolling Returns
Discrete Period
SIP Returns
1M 3M 6M 1Y 3Y 5Y Annualized Returns 3.24 4.01 13.44 40.79 13.48 25.72 Category Avg 5.35 4.69 16.19 41.17 13.60 25.44 Rank within Category 23 17 18 11 5 5 No. of funds within Category 23 22 20 17 12 8 - Loading...
- Loading...
Return Comparison
- This Fund
- BenchmarkBSE Healthcare Index
Choose from Benchmarks
- S&P BSE Sensex
- Nifty 50
- 1M
- 3M
- 6M
- 1Y
- 5Y
Nippon India Pharma Fund-Growth Fund Details
Investment Objective - The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
Fund House | Nippon India Mutual Fund |
Launch Date | Jun 05, 2004 |
Benchmark | BSE Healthcare Index |
Return Since Launch | 20.82% |
Riskometer | Very High |
Type | Open-ended |
Risk Grade | Average |
Return Grade | Above Average |
Nippon India Pharma Fund-Growth Investment Details
Minimum Investment (Rs.) | 5,000.00 |
Minimum Additional Investment (Rs.) | 1,000.00 |
Minimum SIP Investment (Rs.) | 100.00 |
Minimum Withdrawal (Rs.) | 100.00 |
Exit Load Exit load of 1% if redeemed within 1 month. |
Portfolio Allocation
Asset Allocation
Asset Allocation History
Sector Allocation
Market Cap Allocation
Concentration & Valuation Analysis
MAY 2024 | APR 2024 | MAR 2024 | FEB 2024 | JAN 2024 | DEC 2023 | |
---|---|---|---|---|---|---|
Number of Holdings | 31 | 31 | 32 | 31 | 32 | 32 |
Top 5 Company Holdings | 40.18% | 38.9% | 40.36% | 39.86% | 38.76% | 37.29% |
Top 10 Company Holdings | 59.52% | 58.27% | 60.03% | 59.14% | 58.93% | 57.9% |
Company with Highest Exposure | Sun Pharmaceutical Industries (13.37%) | Sun Pharmaceutical Industries (13.81%) | Sun Pharmaceutical Industries (14.91%) | Sun Pharmaceutical Industries (14.51%) | Sun Pharmaceutical Industries (13.5%) | Sun Pharmaceutical Industries (12.76%) |
Number of Sectors | 1 | 1 | 1 | 1 | 1 | 1 |
Top 3 Sector Holdings | 98.34% | 96.17% | 97.15% | 97.94% | 99.23% | 98.54% |
Top 5 Sector Holdings | 98.34% | 96.17% | 97.15% | 97.94% | 99.23% | 98.54% |
Sector with Highest Exposure | Healthcare (98.34%) | Healthcare (96.17%) | Healthcare (97.15%) | Healthcare (97.94%) | Healthcare (99.23%) | Healthcare (98.54%) |
Top Stock Holdings
Sector Holdings in MF
Company Sector Assest(%) P/E EPS-TTM(₹) RETURN 1 YR(%) Sun Pharmaceutical Industries Healthcare 13.37 38.10 39.91 53.14 Lupin Healthcare 7.74 38.59 42.01 102.08 Divi's Laboratories Healthcare 7.52 76.26 60.27 31.94 Cipla Healthcare 6.26 29.01 51.05 54.48 Apollo Hospitals Enterprise Healthcare 5.29 98.98 62.50 22.08 Dr. Reddy's Laboratories Healthcare 4.45 19.15 334.37 29.88 Gland Pharma Healthcare 4.37 - - - Zydus Lifesciences Healthcare 3.77 27.54 38.99 107.94 Vijaya Diagnostic Centre Healthcare 3.59 - - - JB Chemicals & Pharmaceuticals Healthcare 3.16 49.27 35.61 66.67
Peer Comparison
Cumulative Returns
SIP returns
Discrete Returns
Quant Measures
Asset Allocation
Scheme Name NAV(Rs./Unit) Scheme Rating AUM(Rs. Cr) 1M 1Y 3Y 5Y Nippon India Pharma Fund-Growth 446.08 7,160.93 3.24 40.79 13.48 25.72 SBI Healthcare Opportunities Fund-Growth 357.54 2,612.73 5.45 38.76 15.73 26.85 ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Growth 32.21 3,925.29 4.99 47.75 16.38 27.25 UTI Healthcare Fund Regular Plan-Growth 235.39 938.43 5.48 42.56 12.58 24.28 Tata India Pharma & Healthcare Fund Regular-Growth 26.22 899.17 4.78 43.38 15.09 24.76
Risk Ratios
Ratios are calculated using the calendar month returns for the last 3 years
Standard Deviation
Standard Deviation
Standard deviation is the deviation of the fund's return around mean.
Low Volatality
14.36VS14.42Fund Vs Category Avg
Beta
Beta
Beta shows the portfolio risk in relation to the market. A beta of less than 1 means that the fund returns are less volatile compared to the broader market. A beta of more than 1 means that the fund returns are more volatile than the broader markets. A beta equal to 1 means that fund's volatility is in line with the broader market.
High Volatality
0.93VS0.92Fund Vs Category Avg
Sharpe Ratio
Sharpe Ratio
Sharpe ratio is a risk adjusted performance measure. A fund with a higher Sharpe ratio is considered better than a fund with a lower Sharpe ratio.
Better risk-adjusted returns
0.61VS0.56Fund Vs Category Avg
Treynor's Ratio
Treynor's Ratio
Treynor is a risk adjusted performance measure. A fund with a higher Treynor ratio is considered better than a fund with a lower Treynor ratio.
Better risk-adjusted returns
9.38VS8.78Fund Vs Category Avg
Jensen's Alpha
Jensen's Alpha
Alpha shows the ability of the fund manager to outperform the market. A higher Alpha is preferred.
Better risk-adjusted returns
1.08VS0.49Fund Vs Category Avg
Mean Return
Mean Return
Average return generated by the fund during a specified period.
Better average monthly returns
14.09VS13.44Fund Vs Category Avg
Risk Ratio Chart
- Risk Ratio
- Category Average
Fund Manager
- S.R.Sailesh Raj BhanSince Mar 20052 schemes
Mr. Bhan is an MBA (Finance) and CFA. Prior to joining Nippon India Mutual Fund, he has worked with Emkay Share & Stock Broker Pvt. Ltd, Shah & Sequeira Invst. Pvt. Ltd, ICFAI- Securities Research Center Analyst - Equity Research.
Scheme Name Category Nav(Rs./Unit) Scheme Rating Asset(Rs. Cr) 1Y Nippon India Large Cap Fund-Growth Large Cap 85.90 26,925.10 39.35 Nippon India Multi Cap Fund-Growth Multi Cap 285.81 Unrated 31,963.02 50.41
More Nippon India Mutual Fund
Scheme Name | Rating | Asset Size(Cr) | 1M | 3M | 6M | 1Y | 3Y |
---|---|---|---|---|---|---|---|
Nippon India Small Cap Fund - Growth | 46,044.13 | -1.95 | 4.63 | 11.09 | 51.11 | 32.62 | |
CPSE ETF-Growth | 36,337.22 | 5.09 | 32.09 | 56.49 | 103.31 | 51.23 | |
Nippon India Liquid Fund-Growth | 35,418.60 | 0.59 | 1.82 | 3.54 | 7.17 | 5.27 | |
Nippon India Liquid Fund Retail-Growth | 35,418.60 | 0.56 | 1.69 | 3.25 | 6.54 | 4.63 | |
Nippon India Multi Cap Fund-Growth | 26,808.69 | 1.36 | 8.18 | 12.89 | 47.34 | 27.40 | |
Nippon India Growth Fund - Growth | 24,480.78 | -1.05 | 4.87 | 14.90 | 52.89 | 26.50 | |
Nippon India Large Cap Fund-Growth | 22,766.78 | 3.02 | 9.89 | 15.39 | 42.51 | 22.36 | |
Nippon India ELSS Tax Saver Fund-Growth | 14,287.55 | 1.98 | 8.33 | 15.88 | 40.29 | 19.76 | |
Nippon India Arbitrage Fund-Growth | 13,853.85 | 0.60 | 2.11 | 3.66 | 7.47 | 5.40 | |
Nippon India Money Market Fund-Growth | 13,164.78 | 0.72 | 1.91 | 3.65 | 7.63 | 5.66 |
Mutual Fund Tools
Top AMCs
- SBI Mutual Fund
- ICICI Prudential Mutual Fund
- HDFC Mutual Fund
- Nippon India Mutual Fund
- Kotak Mahindra Mutual Fund
- Aditya Birla Sun Life Mutual Fund
- UTI Mutual Fund
- Axis Mutual Fund
- Mirae Asset Mutual Fund
- DSP Mutual Fund
- Edelweiss Mutual Fund
- Tata Mutual Fund
- Bandhan Mutual Fund
- HSBC Mutual Fund
- Franklin Templeton Mutual Fund
1. Nippon India Pharma Fund is Open-ended Sectoral-Pharma Equity scheme which belongs to Nippon India Mutual Fund House.
2. The fund was launched on Jun 05, 2004.
Investment objective & Benchmark
1. The investment objective of the fund is that " The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies. "
2. It is benchmarked against BSE Healthcare Index.
Asset Allocation & Portfolio Composition
1. The asset allocation of the fund comprises around 98.34% in equities, 0.01% in debts and 1.65% in cash & cash equivalents.
2. While the top 10 equity holdings constitute around 59.52% of the assets, the top 3 sectors constitute around 98.34% of the assets.
3. The fund largely follows a Blend oriented style of investing and invests across market capitalisations - around 0.0% in giant & large cap companies, 0.0% in mid cap and 0.0% in small cap companies.
Tax Implications on Nippon India Pharma Fund-Growth
1. Gains are taxed at a rate of 15% (Short-term Capital Gain Tax - STCG) if units are redeemed within 1 year of investment.
2. For units redeemed after 1 year of investment, gains of upto Rs. 1 lakh accruing from those units in a financial year shall be exempted from tax.
3. Gains of more than Rs. 1 lakh will be taxed at a rate of 10% (Long-term Capital Gain Tax - LTCG).
4. For Dividend Distribution Tax, the dividend income from this fund will get added to the income of an investor and taxed according to his/her respective tax slabs.
5. Also, for dividend income in excess of Rs 5,000 in a financial year; the fund house shall deduct a TDS of 10% on such income.
FAQs about Nippon India Pharma Fund-Growth
- Is it safe to invest in Nippon India Pharma Fund?As per SEBI’s latest guidelines to calculate risk grades, investment in the Nippon India Pharma Fund comes under Very High risk category.
- What is the category of Nippon India Pharma Fund?Nippon India Pharma Fund belongs to the Equity : Sectoral-Pharma category of funds.
- How Long should I Invest in Nippon India Pharma Fund?The suggested investment horizon of investing into Nippon India Pharma Fund is >3 years. The suggested investment horizon is the minimum time required for holding investments in the fund to reduce its downside risk and ensure that the returns become more predictable.
- Who manages the Nippon India Pharma Fund?The Nippon India Pharma Fund is managed by Sailesh Raj Bhan (Since Mar 01, 2005).
Date Sources: Mutual Funds, ETFs, and NPS data are sourced from Value Research. All times stamps are reflecting IST (Indian Standard Time). By using this site, you agree to the Terms of Service and Privacy Policy.